Developer docs
API playgroundTry for free, no card

Search company profiles

OpenEvidence

Full company profile

uuid000006z

Namestring
OpenEvidence
Legal namestring
OpenEvidence Inc.
Company typeenum
Private
Founded yearint
2022
Descriptiontext

OpenEvidence is a Miami-based medical AI company founded in 2022 by Daniel Nadler and Zachary Ziegler that builds an evidence-based clinical decision support search engine for verified U.S. healthcare professionals. The platform uses a retrieval-augmented generation architecture trained on peer-reviewed medical literature rather than the open internet, with answers grounded in citable sources and licensed content from the New England Journal of Medicine, JAMA Network, NCCN, Wiley (including the Cochrane Database), and more than 30 medical specialty societies. The core product has expanded into a multi-module workflow suite that includes Visits for ambient clinical documentation, the AI-Integrated Doctor Dialer for HIPAA-secure telehealth, Coding Intelligence for automated CPT/ICD-10/E/M suggestions, Voice Mode for hands-free speech interaction, and Dotflows for clinician-customized prompts, with prescription generation and prior authorization added through a Tandem partnership. The platform is free for verified U.S. clinicians (NPI-credentialed) and processes over one million clinical questions per day across more than 10,000 hospitals and medical centers, with enterprise deployments at Mount Sinai, Cedars-Sinai, and Sutter Health integrated directly into Epic EHR workflows.

Revenue is generated primarily through pharmaceutical and medical device advertising on the platform, supplemented by an emerging enterprise licensing motion at health systems; the company surpassed $100 million in annualized revenue in under a year. OpenEvidence has raised approximately $700 million across multiple rounds, most recently a $250 million Series D in January 2026 at a $12 billion valuation led by Thrive Capital and DST Global, with a syndicate including Google Ventures, Kleiner Perkins, Sequoia Capital, Andreessen Horowitz, Nvidia, and Mayo Clinic. The company operates with fewer than 100 employees, withdrew from EU and UK markets in April 2026 citing EU AI Act uncertainty, and is HIPAA-compliant and SOC 2 Type II certified.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical decision support, medical AI search, evidence-based medicine, physician decision support, healthcare AI platform
Industry2 codes
PRIMARYHLALABAH
Care Navigation, Referral & Digital Front Door Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
SECONDARYHLALAKAA
Virtual Visit & Video Conferencing APIs/SDKs (HIPAA-compliant)
Healthcare & Life Sciences/Telehealth Platforms/Telehealth Infrastructure & Enablement Platforms (video, scheduling, EHR integration)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
Product category
Clinical Decision Support Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical and Medical Device Advertising
TypeAdvertising
Description

Revenue derived from pharmaceutical and medical device advertisements displayed on the platform. The platform is free for healthcare professionals, with advertisers able to target based on physician specialty and browsing behavior. OpenEvidence maintains strict separation between advertising and clinical content.

eweek.com
2Enterprise Platform Licenses
TypeSubscription Recurring
Description

Enterprise deployments at health systems including Cedars-Sinai, Mount Sinai, and Sutter Health integrated directly into Epic EHR workflows. Revenue from enterprise agreements with health systems for widespread clinical adoption.

businesswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Free for verified healthcare professionals
ModelFreemiumBilling cadenceMonthly
Notes

OpenEvidence is free and unlimited for healthcare professionals. Users must register and verify their credentials (NPI number or medical license). The free model is supported by pharmaceutical advertising.

openevidence.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Coding Intelligence
Description

AI-powered medical coding feature providing automatic CPT code suggestions, E/M level recommendations, and ICD-10 diagnoses during doctor-patient visits.

prnewswire.com
+2 more records
Core offering1 text field

OpenEvidence operates a medical AI search engine that lets verified U.S. healthcare professionals ask natural-language clinical questions and receive sourced, evidence-weighted answers grounded in peer-reviewed medical literature, clinical guidelines, and society content. The platform is integrated into Epic EHR workflows at major U.S. health systems and is augmented by modules for ambient clinical documentation (Visits), HIPAA-secure communications (Doctor Dialer), automated medical coding (Coding Intelligence), voice interaction (Voice Mode), and customizable prompts (Dotflows).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 65% of U.S. physicians now use OpenEvidence regularly, up from 50% seven months prior
+3 more records
Product overview1 text field

OpenEvidence is a Miami-based medical AI platform that functions as a clinical decision support system for verified U.S. healthcare professionals. The core product is the OpenEvidence medical search engine, an evidence-based AI copilot that retrieves and synthesizes answers from peer-reviewed literature and clinical guidelines. The platform operates as a unified system with several integrated modules: the core search engine, Visits (ambient clinical documentation and note generation), the AI-Integrated Doctor Dialer (HIPAA-secure calling, messaging, faxing, and voicemail), Coding Intelligence (automated medical coding suggestions), Voice Mode (hands-free speech interaction), and Dotflows (customizable prompts). Additional capabilities include patient handout generation, visit scheduling, and prescription/prior authorization automation via a Tandem partnership. The platform is free for verified U.S. healthcare professionals and generates revenue through pharmaceutical and medical device advertising. It integrates content from NEJM, JAMA, NCCN, Wiley, Cochrane, and 30+ medical societies, and is deployed enterprise-wide at major health systems including Mount Sinai, Cedars-Sinai, and Sutter Health via Epic EHR integration.

Product and service6 records
1OpenEvidence Core Platform
CategoryClinical decision support platform
Description

The flagship medical AI search engine that allows verified U.S. physicians and healthcare professionals to ask natural-language clinical questions and receive sourced, cited answers grounded in peer-reviewed medical literature and clinical guidelines. Integrated into Epic EHR workflows at major health systems (Cedars-Sinai, Mount Sinai, Sutter Health) and free for verified U.S. clinicians.

2Visits
CategoryClinical documentation software
Description

Ambient clinical documentation feature that transcribes doctor-patient encounters in real time, automatically generates structured clinical notes enriched with evidence-backed citations, and allows clinicians to query patient documentation via a built-in AI assistant. Used by verified U.S. healthcare professionals at the point of care.

3AI-Integrated Doctor Dialer
CategoryTelemedicine communications
Description

HIPAA-secure telemedicine communications suite integrated within the OpenEvidence platform, offering customizable caller ID voice calls, secure text messaging, in-app faxing, and straight-to-voicemail outreach between clinicians and patients. Powers approximately 37 million minutes of doctor-patient care communications and includes automatic clinical note creation when combined with Visits.

4Coding Intelligence
CategoryMedical coding and revenue cycle software
Description

AI-powered medical coding module that automatically suggests ICD-10 diagnosis codes, E/M level recommendations, and CPT procedure codes with clinical rationale and expected RVU values during patient encounters. Supports revenue cycle management by surfacing uncommon procedure codes for complex cases prior to claims submission; free for verified U.S. healthcare professionals.

5Voice Mode
CategoryVoice-enabled clinical assistant
Description

Hands-free speech-to-speech AI feature allowing clinicians to receive spoken, evidence-based answers while moving between patient rooms without touching a screen. Sources include NEJM, JAMA, and NCCN guidelines, integrated directly into Epic EHR workflows.

6Dotflows
CategoryAI customization platform
Description

Customization feature that allows verified clinicians to create reusable natural-language prompts shaping how the OpenEvidence platform responds to queries, with a community library for browsing, cloning, and sharing custom Dotflows among verified users.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Society for Neuro-Oncology (SNO)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Landmark partnership designating OpenEvidence as SNO's official generative AI partner, with OpenEvidence's AI-powered clinical decision support platform embedded across SNO's member-facing digital properties. Aims to help clinicians access evidence-based clinical information more quickly amid rapidly evolving medical literature in neuro-oncology.

01net.it
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Partnership to make EchoNext (FDA-approved AI tool that reads ECGs to detect six types of structural heart disease) available to over 500,000 physicians on OpenEvidence's clinical decision platform.

3American Academy of Ophthalmology (AAO)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-12
Description

Strategic partnership to integrate AAO clinical guidelines, including Preferred Practice Pattern Guidelines and Ophthalmic Technology Assessments, into the OpenEvidence platform. Guidelines made freely accessible to ophthalmologists alongside OpenEvidence's existing peer-reviewed medical literature.

glance.eyesoneyecare.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-30
Description

Deployed OpenEvidence enterprise platform systemwide, integrating AI-powered clinical decision support directly into its EHR system to provide real-time, patient-specific medical insights at the point of care. Plans to further customize with institutional care pathways and safety protocols.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-12
Description

Partnership established as part of OpenEvidence's strategy to build new partnerships and expand its market reach beyond core clinical search.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Partnership to integrate ACOG's evidence-based clinical guidance into the AI platform, giving clinicians across specialties access to ob-gyn guidance at the point of care. Collaboration also analyzes clinician search patterns to identify evidence gaps in women's health.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Multi-year collaboration to embed AUA Clinical Practice Guidelines and Clinical Consensus Statements into OpenEvidence's AI-driven clinical decision support platform. Deepens penetration among urologists and supports cross-specialty adoption.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-03
Description

Strategic partnership to add prescription generation and prior authorization submission capabilities to OpenEvidence's clinical decision support platform. The integration embeds prescription automation directly into EHR workflows to reduce administrative burdens on clinicians, accelerate treatment, and improve patient access to medications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

Enterprise-wide deployment of OpenEvidence integrated directly into Epic EHR system. First large-scale rollout extending access to the entire clinical workforce including physicians, nurses, and pharmacists.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-29
Description

Collaboration to integrate ACC clinical guidance into the OpenEvidence platform, showcased at ACC conference. Includes use cases like SGLT2 inhibitor timing and DAPT duration, supported by ACC/AHA citations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-13
Description

Partnership to expand access to trusted, expert-reviewed rare disease information for clinicians, patients, and families worldwide. Will combine AI-powered synthesis of biomedical literature with expert review to build a library of more than 3,000 rare disease summaries.

12Wiley
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Strategic partnership to bring Wiley's trusted scientific and medical content into OpenEvidence, including the Cochrane Database of Systematic Reviews, over 400 Wiley journals and books, and major medical references spanning cardiology, oncology, neurology, and other specialties.

openevidence.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-12
Description

Partnership to integrate AI-powered clinical decision support within Epic EHR workflows, enabling physicians to quickly access relevant guidelines and studies through natural language searches.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Licensing agreement to make NCCN's trusted, evidence-based oncology guidelines (NCCN Guidelines and JNCCN) accessible through OpenEvidence's medical AI technology. Enables healthcare professionals to access NCCN recommendations via natural-language search.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-19
Description

Multi-year content agreement to provide OpenEvidence with all published content and multimedia from NEJM, NEJM Evidence, NEJM AI, NEJM Catalyst, and NEJM Journal Watch from 1990 forward. OpenEvidence designated as Official AI Partner of The New England Journal of Medicine.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The incumbent evidence-based clinical decision support resource used by most U.S. physicians. Directly comparable to OpenEvidence as a peer-reviewed reference tool at the point of care, though it relies on human-authored topic reviews rather than generative AI.

TypeDirect peer
Description

Another leading evidence-based clinical decision support platform sold to hospitals and physicians. Comparable in workflow (point-of-care evidence lookup) and buyer (health systems and individual clinicians) but predates the LLM era.

TypeBroad incumbent
Description

Largest U.S. physician network with workflow tools, telehealth (Dialer), and pharma marketing monetization. Comparable target audience (verified U.S. physicians) and a parallel pharma-advertising revenue model, but broader in scope than clinical evidence.

TypeDirect peer
Description

AI company focused on ambient clinical documentation and conversation-to-note generation for clinicians, integrated with Epic. Closest direct competitor in the AI clinical workflow category that OpenEvidence is expanding into with its Visits module.

TypeDirect peer
Description

AI voice assistant for clinicians that automates documentation, coding and other administrative tasks. Overlaps with OpenEvidence's Visits, Voice Mode, and Coding Intelligence modules in selling ambient AI to health systems.

TypeEmerging player
Description

Healthcare-focused LLM company building safety-tuned foundation models for clinical use cases. A potential complement/competitor to OpenEvidence's RAG approach if its models become embedded in clinical workflows directly.

TypeEmerging player
Description

AI clinical decision support platform aimed at clinicians for differential diagnosis and treatment planning. Overlaps with OpenEvidence's evidence-search and clinical decision support functionality for individual practitioners.

TypeBroad incumbent
Description

Long-standing point-of-care drug and clinical reference app widely used by U.S. physicians. Comparable as a physician-facing clinical reference, with pharma-sponsored content monetization akin to OpenEvidence's model.

TypeBroad incumbent
Description

Parent group behind UpToDate and other evidence-based clinical tools. A large, established competitor with the content depth, hospital relationships, and capital to challenge AI-native entrants in clinical decision support.

TypeOthers
Description

Medical knowledge-sharing platform for healthcare professionals. Adjacent in serving as a physician-facing clinical knowledge community, though narrower in scope than OpenEvidence's evidence-based search engine.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors28 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OpenEvidence

Clinical Decision Support Softwareopenevidence.com

What OpenEvidence does

OpenEvidence is a Miami-based medical AI company founded in 2022 by Daniel Nadler and Zachary Ziegler that builds an evidence-based clinical decision support search engine for verified U.S. healthcare professionals. The platform uses a retrieval-augmented generation architecture trained on peer-reviewed medical literature rather than the open internet, with answers grounded in citable sources and licensed content from the New England Journal of Medicine, JAMA Network, NCCN, Wiley (including the Cochrane Database), and more than 30 medical specialty societies. The core product has expanded into a multi-module workflow suite that includes Visits for ambient clinical documentation, the AI-Integrated Doctor Dialer for HIPAA-secure telehealth, Coding Intelligence for automated CPT/ICD-10/E/M suggestions, Voice Mode for hands-free speech interaction, and Dotflows for clinician-customized prompts, with prescription generation and prior authorization added through a Tandem partnership. The platform is free for verified U.S. clinicians (NPI-credentialed) and processes over one million clinical questions per day across more than 10,000 hospitals and medical centers, with enterprise deployments at Mount Sinai, Cedars-Sinai, and Sutter Health integrated directly into Epic EHR workflows.

Revenue is generated primarily through pharmaceutical and medical device advertising on the platform, supplemented by an emerging enterprise licensing motion at health systems; the company surpassed $100 million in annualized revenue in under a year. OpenEvidence has raised approximately $700 million across multiple rounds, most recently a $250 million Series D in January 2026 at a $12 billion valuation led by Thrive Capital and DST Global, with a syndicate including Google Ventures, Kleiner Perkins, Sequoia Capital, Andreessen Horowitz, Nvidia, and Mayo Clinic. The company operates with fewer than 100 employees, withdrew from EU and UK markets in April 2026 citing EU AI Act uncertainty, and is HIPAA-compliant and SOC 2 Type II certified.

OpenEvidence firmographics

Firmographics
Name
OpenEvidence
Legal name
OpenEvidence Inc.
Website
https://openevidence.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

OpenEvidence industry classification

Industry
Product category
Clinical Decision Support Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000)
akta.pro industry
PRIMARYHLALABAH
Care Navigation, Referral & Digital Front Door Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
SECONDARYHLALAKAA
Virtual Visit & Video Conferencing APIs/SDKs (HIPAA-compliant)
Healthcare & Life Sciences/Telehealth Platforms/Telehealth Infrastructure & Enablement Platforms (video, scheduling, EHR integration)

Keywords

  • Clinical decision support
  • Medical AI search
  • Evidence-based medicine
  • Physician decision support
  • Healthcare AI platform

Where OpenEvidence is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OpenEvidence business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical and Medical Device Advertising: Revenue derived from pharmaceutical and medical device advertisements displayed on the platform. The platform is free for healthcare professionals, with advertisers able to target based on physician specialty and browsing behavior. OpenEvidence maintains strict separation between advertising and clinical content.
  2. Enterprise Platform Licenses: Enterprise deployments at health systems including Cedars-Sinai, Mount Sinai, and Sutter Health integrated directly into Epic EHR workflows. Revenue from enterprise agreements with health systems for widespread clinical adoption.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree for verified healthcare professionals

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

OpenEvidence product offering

Product offering

Core offering

OpenEvidence operates a medical AI search engine that lets verified U.S. healthcare professionals ask natural-language clinical questions and receive sourced, evidence-weighted answers grounded in peer-reviewed medical literature, clinical guidelines, and society content. The platform is integrated into Epic EHR workflows at major U.S. health systems and is augmented by modules for ambient clinical documentation (Visits), HIPAA-secure communications (Doctor Dialer), automated medical coding (Coding Intelligence), voice interaction (Voice Mode), and customizable prompts (Dotflows).

Product overview

OpenEvidence is a Miami-based medical AI platform that functions as a clinical decision support system for verified U.S. healthcare professionals. The core product is the OpenEvidence medical search engine, an evidence-based AI copilot that retrieves and synthesizes answers from peer-reviewed literature and clinical guidelines. The platform operates as a unified system with several integrated modules: the core search engine, Visits (ambient clinical documentation and note generation), the AI-Integrated Doctor Dialer (HIPAA-secure calling, messaging, faxing, and voicemail), Coding Intelligence (automated medical coding suggestions), Voice Mode (hands-free speech interaction), and Dotflows (customizable prompts). Additional capabilities include patient handout generation, visit scheduling, and prescription/prior authorization automation via a Tandem partnership. The platform is free for verified U.S. healthcare professionals and generates revenue through pharmaceutical and medical device advertising. It integrates content from NEJM, JAMA, NCCN, Wiley, Cochrane, and 30+ medical societies, and is deployed enterprise-wide at major health systems including Mount Sinai, Cedars-Sinai, and Sutter Health via Epic EHR integration.

Differentiator

Problem solved

Functional benefit

Brands

  • Coding Intelligence: AI-powered medical coding feature providing automatic CPT code suggestions, E/M level recommendations, and ICD-10 diagnoses during doctor-patient visits.
  • Doctor Dialer
  • Visits

Products and services

  • OpenEvidence Core Platform The flagship medical AI search engine that allows verified U.S. physicians and healthcare professionals to ask natural-language clinical questions and receive sourced, cited answers grounded in peer-reviewed medical literature and clinical guidelines. Integrated into Epic EHR workflows at major health systems (Cedars-Sinai, Mount Sinai, Sutter Health) and free for verified U.S. clinicians.
  • Visits Ambient clinical documentation feature that transcribes doctor-patient encounters in real time, automatically generates structured clinical notes enriched with evidence-backed citations, and allows clinicians to query patient documentation via a built-in AI assistant. Used by verified U.S. healthcare professionals at the point of care.
  • AI-Integrated Doctor Dialer HIPAA-secure telemedicine communications suite integrated within the OpenEvidence platform, offering customizable caller ID voice calls, secure text messaging, in-app faxing, and straight-to-voicemail outreach between clinicians and patients. Powers approximately 37 million minutes of doctor-patient care communications and includes automatic clinical note creation when combined with Visits.
  • Coding Intelligence AI-powered medical coding module that automatically suggests ICD-10 diagnosis codes, E/M level recommendations, and CPT procedure codes with clinical rationale and expected RVU values during patient encounters. Supports revenue cycle management by surfacing uncommon procedure codes for complex cases prior to claims submission; free for verified U.S. healthcare professionals.
  • Voice Mode Hands-free speech-to-speech AI feature allowing clinicians to receive spoken, evidence-based answers while moving between patient rooms without touching a screen. Sources include NEJM, JAMA, and NCCN guidelines, integrated directly into Epic EHR workflows.
  • Dotflows Customization feature that allows verified clinicians to create reusable natural-language prompts shaping how the OpenEvidence platform responds to queries, with a community library for browsing, cloning, and sharing custom Dotflows among verified users.

Quantifiable outcome

  • 65% of U.S. physicians now use OpenEvidence regularly, up from 50% seven months prior
  • +3 more outcomes

Companies that use OpenEvidence

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

OpenEvidence technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature6 records

OpenEvidence partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • Society for Neuro-Oncology (SNO)coreStrategic or Co-development Partner · 23 June 2026Landmark partnership designating OpenEvidence as SNO's official generative AI partner, with OpenEvidence's AI-powered clinical decision support platform embedded across SNO's member-facing digital properties. Aims to help clinicians access evidence-based clinical information more quickly amid rapidly evolving medical literature in neuro-oncology.
  • Pathway LabsminorStrategic or Co-development Partner · 23 June 2026Partnership to make EchoNext (FDA-approved AI tool that reads ECGs to detect six types of structural heart disease) available to over 500,000 physicians on OpenEvidence's clinical decision platform.
  • American Academy of Ophthalmology (AAO)coreStrategic or Co-development Partner · 12 June 2026Strategic partnership to integrate AAO clinical guidelines, including Preferred Practice Pattern Guidelines and Ophthalmic Technology Assessments, into the OpenEvidence platform. Guidelines made freely accessible to ophthalmologists alongside OpenEvidence's existing peer-reviewed medical literature.
  • Cedars-SinaicoreStrategic or Co-development Partner · 30 May 2026Deployed OpenEvidence enterprise platform systemwide, integrating AI-powered clinical decision support directly into its EHR system to provide real-time, patient-specific medical insights at the point of care. Plans to further customize with institutional care pathways and safety protocols.
  • Society of Surgical OncologyminorStrategic or Co-development Partner · 12 May 2026Partnership established as part of OpenEvidence's strategy to build new partnerships and expand its market reach beyond core clinical search.
  • American College of Obstetricians and Gynecologists (ACOG)coreStrategic or Co-development Partner · 6 May 2026Partnership to integrate ACOG's evidence-based clinical guidance into the AI platform, giving clinicians across specialties access to ob-gyn guidance at the point of care. Collaboration also analyzes clinician search patterns to identify evidence gaps in women's health.
  • American Urological Association (AUA)coreStrategic or Co-development Partner · 30 April 2026Multi-year collaboration to embed AUA Clinical Practice Guidelines and Clinical Consensus Statements into OpenEvidence's AI-driven clinical decision support platform. Deepens penetration among urologists and supports cross-specialty adoption.
  • TandemcoreStrategic or Co-development Partner · 3 April 2026Strategic partnership to add prescription generation and prior authorization submission capabilities to OpenEvidence's clinical decision support platform. The integration embeds prescription automation directly into EHR workflows to reduce administrative burdens on clinicians, accelerate treatment, and improve patient access to medications.
  • Mount Sinai Health SystemcoreStrategic or Co-development Partner · 2 April 2026Enterprise-wide deployment of OpenEvidence integrated directly into Epic EHR system. First large-scale rollout extending access to the entire clinical workforce including physicians, nurses, and pharmacists.
  • American College of Cardiology (ACC)coreStrategic or Co-development Partner · 29 March 2026Collaboration to integrate ACC clinical guidance into the OpenEvidence platform, showcased at ACC conference. Includes use cases like SGLT2 inhibitor timing and DAPT duration, supported by ACC/AHA citations.
  • National Organization for Rare Disorders (NORD)coreStrategic or Co-development Partner · 13 March 2026Partnership to expand access to trusted, expert-reviewed rare disease information for clinicians, patients, and families worldwide. Will combine AI-powered synthesis of biomedical literature with expert review to build a library of more than 3,000 rare disease summaries.
  • WileycoreStrategic or Co-development Partner · 3 March 2026Strategic partnership to bring Wiley's trusted scientific and medical content into OpenEvidence, including the Cochrane Database of Systematic Reviews, over 400 Wiley journals and books, and major medical references spanning cardiology, oncology, neurology, and other specialties.
  • Sutter HealthcoreStrategic or Co-development Partner · 12 February 2026Partnership to integrate AI-powered clinical decision support within Epic EHR workflows, enabling physicians to quickly access relevant guidelines and studies through natural language searches.
  • National Comprehensive Cancer Network (NCCN)coreStrategic or Co-development Partner · 5 November 2025Licensing agreement to make NCCN's trusted, evidence-based oncology guidelines (NCCN Guidelines and JNCCN) accessible through OpenEvidence's medical AI technology. Enables healthcare professionals to access NCCN recommendations via natural-language search.
  • NEJM GroupcoreStrategic or Co-development Partner · 19 February 2025Multi-year content agreement to provide OpenEvidence with all published content and multimedia from NEJM, NEJM Evidence, NEJM AI, NEJM Catalyst, and NEJM Journal Watch from 1990 forward. OpenEvidence designated as Official AI Partner of The New England Journal of Medicine.

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

OpenEvidence competitors and assessment

Company assessment

Direct peers

  • UpToDate (Wolters Kluwer): The incumbent evidence-based clinical decision support resource used by most U.S. physicians. Directly comparable to OpenEvidence as a peer-reviewed reference tool at the point of care, though it relies on human-authored topic reviews rather than generative AI.
  • DynaMed (EBSCO): Another leading evidence-based clinical decision support platform sold to hospitals and physicians. Comparable in workflow (point-of-care evidence lookup) and buyer (health systems and individual clinicians) but predates the LLM era.
  • Abridge: AI company focused on ambient clinical documentation and conversation-to-note generation for clinicians, integrated with Epic. Closest direct competitor in the AI clinical workflow category that OpenEvidence is expanding into with its Visits module.
  • Suki AI: AI voice assistant for clinicians that automates documentation, coding and other administrative tasks. Overlaps with OpenEvidence's Visits, Voice Mode, and Coding Intelligence modules in selling ambient AI to health systems.

Broad incumbents

  • Doximity: Largest U.S. physician network with workflow tools, telehealth (Dialer), and pharma marketing monetization. Comparable target audience (verified U.S. physicians) and a parallel pharma-advertising revenue model, but broader in scope than clinical evidence.
  • Epocrates (athenahealth): Long-standing point-of-care drug and clinical reference app widely used by U.S. physicians. Comparable as a physician-facing clinical reference, with pharma-sponsored content monetization akin to OpenEvidence's model.
  • Wolters Kluwer Clinical Effectiveness: Parent group behind UpToDate and other evidence-based clinical tools. A large, established competitor with the content depth, hospital relationships, and capital to challenge AI-native entrants in clinical decision support.

Emerging players

  • Hippocratic AI: Healthcare-focused LLM company building safety-tuned foundation models for clinical use cases. A potential complement/competitor to OpenEvidence's RAG approach if its models become embedded in clinical workflows directly.
  • Glass Health: AI clinical decision support platform aimed at clinicians for differential diagnosis and treatment planning. Overlaps with OpenEvidence's evidence-search and clinical decision support functionality for individual practitioners.

Others

  • Figure 1 (Health Tech): Medical knowledge-sharing platform for healthcare professionals. Adjacent in serving as a physician-facing clinical knowledge community, though narrower in scope than OpenEvidence's evidence-based search engine.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

OpenEvidence social profiles

Digital presence

OpenEvidence compliance and trust

Trust signal

Compliance3 records

OpenEvidence financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OpenEvidence leadership team

Management profile

Number of profiles

Profiles3 records

OpenEvidence funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OpenEvidence M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OpenEvidence

What does OpenEvidence do?

OpenEvidence operates a medical AI search engine that lets verified U.S. healthcare professionals ask natural-language clinical questions and receive sourced, evidence-weighted answers grounded in peer-reviewed medical literature, clinical guidelines, and society content. The platform is integrated into Epic EHR workflows at major U.S. health systems and is augmented by modules for ambient clinical documentation (Visits), HIPAA-secure communications (Doctor Dialer), automated medical coding (Coding Intelligence), voice interaction (Voice Mode), and customizable prompts (Dotflows).

Is OpenEvidence a public or private company?

OpenEvidence is a private company. It is classified as venture growth investor backed and is currently operating.

When was OpenEvidence founded?

OpenEvidence was founded in 2022. It employs 101 to 250 people.

Where is OpenEvidence based?

OpenEvidence is headquartered in Miami, United States, in the North America region.

How does OpenEvidence make money?

Two revenue lines are on record. Pharmaceutical and Medical Device Advertising is the primary driver. The others are enterprise Platform Licenses.

Who are OpenEvidence's main competitors?

Direct peers on record are UpToDate (Wolters Kluwer), DynaMed (EBSCO), Abridge and Suki AI. Broad incumbents are Doximity, Epocrates (athenahealth) and Wolters Kluwer Clinical Effectiveness. Emerging players are Hippocratic AI and Glass Health. Figure 1 (Health Tech) is listed as an others.

Does OpenEvidence have an API?

No public API is recorded for OpenEvidence.

What industry is OpenEvidence in?

OpenEvidence's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLALABAH, Care Navigation, Referral & Digital Front Door Platforms, with a secondary code of HLALAKAA, Virtual Visit & Video Conferencing APIs/SDKs (HIPAA-compliant). Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MDPIVirtual Reality for Patient Care: A State-of-the-Art Review of Clinical Applications Based on AI-Assisted Literature RetrievalA study compared AI-assisted literature retrieval using OpenEvidence and ChatGPT against a structured Scopus search for clinical applications of immersive technologies since 2023. OpenEvidence retrieved 95 articles covering all 16 predefined areas, while ChatGPT retrieved 22, and together they identified only 6 of 56 highly cited publications (10.7%). The findings describe thematic and bibliometric coverage but do not establish completeness for evidence synthesis.MedCity NewsDoc at HLTH: I Can’t Imagine Seeing Patients Without AIAt HLTH, Dr. Kyu Rhee said AI winters are over, while Dr. Sarah Russell said she can't imagine seeing patients without AI, using OpenEvidence to check side effects. Oura announced a $625M acquisition of Counsel Health to integrate its medical AI chatbot into its app, aiming to expand care access.SemaforMedical students should ‘learn the hard way,’ AI startup CEO saysOpenEvidence CEO Daniel Nadler advised medical students to take paper exams and master material despite AI use, citing acute cognitive offloading risks. The startup, which synthesizes medical information with AI, has a $15 billion valuation. Formation Bio CEO Benjamine Liu also spoke on AI's role in pharma.MedTech DiveApple, OpenEvidence launch conversational health AI study and appApple announced a virtual research study and app with OpenEvidence to examine consumer trust, response quality, and behavior change in conversational health AI. The study, open to up to 200,000 U.S. participants, will not train AI models and requires opt-in data sharing. Findings may inform Apple's healthcare AI product development.MobiHealthNewsApple launches research study with OpenEvidenceApple launched a study with OpenEvidence to examine how people interact with conversational healthcare AI, including an app that answers health questions with citations. The U.S. study will include up to 200,000 participants aged 21 and older with an iPhone 15 Pro or later, and data will not train AI models.Business Wire BlogEvery Cure and OpenEvidence Partner to Repurpose Drugs Where Commercial Incentives Fall ShortEvery Cure and OpenEvidence announced a partnership to repurpose existing medicines for patients with no commercial incentive. The collaboration uses OpenEvidence's AI models and physician network to evaluate hypotheses, match patients to trials, and disseminate evidence. The partnership aims to accelerate access to repurposed treatments for rare and underserved diseases.Healthcare DiveApple, OpenEvidence launch conversational health AI study and appApple announced a virtual research study and app with OpenEvidence to examine consumer trust, response quality, and behavior change in conversational health AI. The study, open to up to 200,000 U.S. participants, will not train AI models and requires opt-in data sharing. Findings may inform Apple's healthcare AI product development.MintApple launches AI health study app in partnership with OpenEvidence: Who can participate and how it works | MintApple launched a US health AI study app with OpenEvidence on Sunday, targeting up to 200,000 participants aged 21+ with iPhone 15 or later. The app provides clinically backed answers from medical journals and lets users rate responses and share health data via HealthKit. Apple has not confirmed whether the study will lead to an AI-powered Siri or Health app feature.STATApple and OpenEvidence launch experimental health chat appApple and OpenEvidence launched a study on an AI-powered health chat app at the HLTH conference in Las Vegas. The study aims to understand user trust, comprehension, and response quality, with OpenEvidence as a clinically grounded partner.WsjDoctors Have a New AssistantOpenEvidence, co-founded by Daniel Nadler, provides an AI assistant for registered physicians, trained on peer-reviewed journals. It handles about one query per patient visit, with 47 million queries in October. The company aims to lower all-cause mortality in the U.S.